SANUWAVE Announces Third Quarter Attendance at Eight Medical Conferences
SUWANEE, GA. , June 28, 2018 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (OTCQB: SNWV) SANUWAVE is pleased to announce that since receiving clearance from the FDA in late December 2017, its presence has been increasing in the medical device field through attendance at various trade shows around the globe. SANUWAVE’s network of partners spans throughout Europe, South America, Australia, and most recently Central America and Southeast Asia. All parties continue to share awareness methodologies and best practices with regards to effective sales, marketing materials, clinical studies, and training techniques.
SANUWAVE will have a presence at the following eight exhibitions in the third quarter:
- 2nd Congress of Diabetic Limb Salvage in Asia (July 7-9) with Kove in Seoul, Korea www.dlsasia.org/
- ASEAN Association of Southeast Asian Nations Wound Summit (July 20-21) with FKS in Kucking, Sarawak, Malaysia http://www.mswcp.org/asean-wound-summit-2018/
- CBE Center for Biofilm Engineering at Montana State Biofilm Conference (July 24-26) in Bozeman, MT www.biofilm.montana.edu
- AMP Amputation Prevention Symposium (August 8-11) in Chicago, IL https://www.emedevents.com/c/medical-conferences-2018/the-amputation-prevention-symposium-amp-2018
- APWCA American Professional Wound Care Association (September 6-8) in Baltimore, MD www.apwca.org
- French National Congress on Sport Medicine (September 20 to 22) with Matek in Le Havre, France http://www.congres-sfmes-sfts.com/fr/partenaires/partenaire
- The Pisa International Diabetic Foot Course (September 19-22) with Matek in Pisa, Italy www.diabeticfootcourses.org
- Global Wound Conference (September 21-23) with FKS in Kuala Lumpur and Malaysia www.woundconference.com.my/gwc2018/
Shri Parikh, President of SANUWAVE stated, “We are excited about our attendance at a robust number of trade shows across the globe this fall. SANUWAVE, in connection with our partners, is excited to increase the exposure of dermaPACE® which is the only FDA cleared shockwave treatment available for DFUs (Diabetic Foot Ulcers). In the third quarter we are successfully expanding our reach towards treating more patients to combat the devastating effects of diabetes related complications.”
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (OTCQB:SNWV) (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE® technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is US FDA cleared for the treatment of Diabetic Foot Ulcers. The device is also CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, South Korea, Australia and New Zealand. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shock wave technology for non-medical uses, including energy, water, food and industrial markets.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
For additional information about the company, visit www.SANUWAVE.com.
CONTACT: Contacts: Millennium Park Capital LLC Christopher Wynne 312-724-7845 cwynne@mparkcm.com SANUWAVE Health, Inc. Kevin Richardson II Chairman of the Board 978-922-2447 investorrelations@sanuwave.com
© 2018 GlobeNewswire, Inc. All Rights Reserved.
Moderna (Nasdaq: MRNA) Announces Publication in The New England Journal of Medicine of Interim Results From Older Adult Age Cohorts in Phase 1 Study of its mRNA Vaccine Against COVID-19 (mRNA-1273)
